Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

Flavio Kruter; Mario Eisenberger; Victoria Sinibaldi; Christine Engstrom; Maria Jacobs; Jeffrey Abrams; Chandra Belani; William Gray; Steven Krasnow

doi:10.1007/BF00873122

Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

Flavio Kruter, Mario Eisenberger, Victoria Sinibaldi, Christine Engstrom, Maria Jacobs, Jeffrey Abrams, Chandra Belani, William Gray, Steven Krasnow

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227 + days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.

Original language	English (US)
Pages (from-to)	89-91
Number of pages	3
Journal	Investigational New Drugs
Volume	10
Issue number	2
DOIs	https://doi.org/10.1007/BF00873122
State	Published - Jun 1992

All Science Journal Classification (ASJC) codes

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00873122

Cite this

@article{48ca31d6d35c4ec383978a3e88b093a5,

title = "Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck",

abstract = "Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227 + days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.",

author = "Flavio Kruter and Mario Eisenberger and Victoria Sinibaldi and Christine Engstrom and Maria Jacobs and Jeffrey Abrams and Chandra Belani and William Gray and Steven Krasnow",

year = "1992",

month = jun,

doi = "10.1007/BF00873122",

language = "English (US)",

volume = "10",

pages = "89--91",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

AU - Kruter, Flavio

AU - Eisenberger, Mario

AU - Sinibaldi, Victoria

AU - Engstrom, Christine

AU - Jacobs, Maria

AU - Abrams, Jeffrey

AU - Belani, Chandra

AU - Gray, William

AU - Krasnow, Steven

PY - 1992/6

Y1 - 1992/6

N2 - Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227 + days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.

AB - Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227 + days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0026638305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026638305&partnerID=8YFLogxK

U2 - 10.1007/BF00873122

DO - 10.1007/BF00873122

M3 - Article

C2 - 1500270

AN - SCOPUS:0026638305

SN - 0167-6997

VL - 10

SP - 89

EP - 91

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this